PubMed

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?

Frizzell KM, Kraus WL.

Breast Cancer Res. 2009;11(6):111. Epub 2009 Nov 26.PMID: 20017885 [PubMed - in process]Related articlesFree article

The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.

De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX.

Int J Biol Sci. 2006;2(4):179-85. Epub 2006 Jun 10.PMID: 16810332 [PubMed - indexed for MEDLINE]Related articlesFree article

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.

Kyle S, Thomas HD, Mitchell J, Curtin NJ.

Br J Radiol. 2008 Oct;81 Spec No 1:S6-11.PMID: 18820000 [PubMed - indexed for MEDLINE]Related articles

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

De Soto JA, Deng CX.

Int J Med Sci. 2006 Jul 15;3(4):117-23.PMID: 16906222 [PubMed]Related articlesFree article

The potential of PARP inhibitors in genetic breast and ovarian cancers.

Drew Y, Calvert H.

Ann N Y Acad Sci. 2008 Sep;1138:136-45.PMID: 18837894 [PubMed - indexed for MEDLINE]Related articles

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, Smith GC, Martin NM, O'Connor M, Clarke AR.

Cancer Res. 2009 May 1;69(9):3850-5. Epub 2009 Apr 21.PMID: 19383921 [PubMed - indexed for MEDLINE]Related articles

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

Williamson CT, Muzik H, Turhan AG, Zamò A, O'Connor MJ, Bebb DG, Lees-Miller SP.

Mol Cancer Ther. 2010 Feb;9(2):347-57. Epub 2010 Feb 2.PMID: 20124459 [PubMed - in process]Related articles

Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.

Rubinstein WS.

Fam Cancer. 2008;7(1):83-9. Epub 2007 Jul 12. Review.PMID: 17624601 [PubMed - indexed for MEDLINE]Related articles

Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.

Comen EA, Robson M.

Cancer J. 2010 Jan-Feb;16(1):48-52.PMID: 20164690 [PubMed - in process]Related articles

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.

Gien LT, Mackay HJ.

J Oncol. 2010;2010:151750. Epub 2009 Dec 16.PMID: 20049345 [PubMed - in process]Related articlesFree article

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A.

Cancer Biol Ther. 2005 Sep;4(9):934-6. Epub 2005 Sep 1.PMID: 16251802 [PubMed - indexed for MEDLINE]Related articlesFree article

A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.

Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, Izraeli S, Cohen-Armon M.

Breast Cancer Res. 2009;11(6):R78. Epub 2009 Nov 9.PMID: 19891779 [PubMed - in process]Related articlesFree article

BRCA in breast cancer: From risk assessment to therapeutic prediction.

Diamond JR, Borges VF, Eckhardt SG, Jimeno A.

Drug News Perspect. 2009 Dec;22(10):603-8.PMID: 20140280 [PubMed - in process]Related articles

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.

Wang W, Figg WD.

Cancer Biol Ther. 2008 Jul;7(7):1004-5. Review.PMID: 18720553 [PubMed - indexed for MEDLINE]Related articlesFree article

PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR, Oliver FJ.

Free Radic Biol Med. 2009 Jul 1;47(1):13-26. Epub 2009 Apr 10. Review.PMID: 19362586 [PubMed - indexed for MEDLINE]Related articles

The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.

Drew Y, Plummer R.

Curr Opin Obstet Gynecol. 2010 Feb;22(1):67-71.PMID: 19934756 [PubMed - in process]Related articles

Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.

Whitacre CM, Zborowska E, Willson JK, Berger NA.

Clin Cancer Res. 1999 Mar;5(3):665-72.PMID: 10100720 [PubMed - indexed for MEDLINE]Related articlesFree article

Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.

Rauh-Adelmann C, Lau KM, Sabeti N, Long JP, Mok SC, Ho SM.

Mol Carcinog. 2000 Aug;28(4):236-46.PMID: 10972993 [PubMed - indexed for MEDLINE]Related articles

Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.

Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL.

J Clin Oncol. 2001 Apr 15;19(8):2247-53.PMID: 11304778 [PubMed - indexed for MEDLINE]Related articles

Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.

Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.

Gynecol Oncol. 2005 May;97(2):457-67.PMID: 15863145 [PubMed - indexed for MEDLINE]Related articles